<DOC>
	<DOC>NCT03076021</DOC>
	<brief_summary>Specific Aim: To investigate if isotretinoin (13-cis-retinoic acid) administration decreases CYP2D6 activity in adolescent patients.</brief_summary>
	<brief_title>Effects of Isotretinoin on CYP2D6 Activity</brief_title>
	<detailed_description>In this aim, we will conduct a drug-drug interaction study evaluating the effects of 13-cis-retinoic acid on non-induced CYP2D6 activity in adolescent patients. Secondary analysis will evaluate the relationship between retinoid concentrations and CYP2D6 activity in these special populations</detailed_description>
	<mesh_term>Isotretinoin</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<criteria>Nonpregnant Adolescent (1221 years of age) Patients with severe acne that are expected to receive isotretinoin for therapeutic reasons Weight &lt; 80 lbs Allergy or adverse reaction to dextromethorphan, vitamin A or isotretinoin Pregnant or planning to become pregnant Unable to follow isotretinoin risk evaluation and mitigation strategies (REMS) program (also known as iPLEDGE program) Chronic or persistent cough accompanying asthma, smoking or COPD, Productive cough, Fever, Known kidney disease, Known liver disease, Diabetes Obesity, BMI â‰¥ 30 kg/m2 Bipolar disease, Attention deficit disorder, Social phobia, Concurrent or use within 14 days of drugs known to interact with DM or CYP2D6 or drugs known to increase the risk of adverse effects from DM Concurrent use of any other product containing dextromethorphan Consuming foods, beverages or dietary supplements known to interact with DM or CYP2D6 Unable to give written informed consent/assent, Inability to fast for 4 hours prior to study. Wards of the State</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>